二、董事会会议审议情况 （一）审议通过《关于<2024 年年度报告>及其摘要的议案》 经审议，董事会认为：公司 2024 年年度报告全文及其摘要的内容真实、准 确、完整地反映了公司 2024 年度经营的实际情况，不存在任何虚假记载、误导 性陈述或者重大遗漏；报告编制和审核的程序符合法律、行政法规的要求，符合 中国证监会和深交所的相关规定，同意对外报出。 证券代码：301096 证券简称：百诚医药 公告编号：2025-020 杭州百诚医药科技股份有限公司 第四届董事会第二次会议决议公告 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公 告中的虚假记载、误导性陈述或者重大遗漏承担责任。 一、董事会会议召开情况 杭州百诚医药科技股份有限公司（以下简称"公司"）第四届董事会第二次会 议于 2025 年 4 月 22 日在公司会议室以现场结合通讯的方式召开。会议通知已于 2025 年 4 月 11 日通过电话、邮件的方式送达各位董事。本次会议应出席董事 9 人，实际出席董事 9 人（其中四位董事以通讯方式出席）。 会议由董事长楼金芳女士主持，公司监事、高级管理人员列席会议。会议召 开符合有关法律、法规 ...

杭州百诚医药科技股份有限公司（以下简称"公司"）于 2025 年 4 月 22 日召开 第四届董事会第二次会议和第四届监事会第二次会议，均全票审议通过了《关于公司 2024 年度利润分配方案的议案》，本议案尚需提交 2024 年年度股东大会审议。 二、2024 年度利润分配方案情况 证券代码：301096 证券简称：百诚医药 公告编号：2025-023 杭州百诚医药科技股份有限公司 关于公司 2024 年度利润分配方案的公告 本公司全体董事、高级管理人员保证公告内容的真实、准确和完整，并对公告 中的虚假记载、误导性陈述或者重大遗漏承担责任。 一、审议程序 要充足的资金保障持续、稳定、健康发展，提升公司市场占有率和市场竞争力，提高 抗风险能力，更好地维护全体股东的长远利益。因此，公司决定 2024 年度拟不进行 利润分配。 根据天健会计师事务所（特殊普通合伙）审计，2024 年度实现归属于母公司股东 的净亏损 52,742,809.58 元。根据《上市公司监管指引第 3 号—上市公司现金分红》 《公司章程》及公司《未来三年（2024 年—2026 年）股东分红回报规划》等的有关规 定，因公司 2024 年度合并 ...

Financial Performance - The company's operating revenue for 2024 was ¥801,923,244.22, a decrease of 21.18% compared to ¥1,017,448,123.50 in 2023[21]. - The net profit attributable to shareholders for 2024 was -¥52,742,809.58, representing a decline of 119.39% from ¥271,966,149.52 in 2023[21]. - The cash flow from operating activities for 2024 was -¥195,856,925.64, a significant drop of 316.53% compared to ¥90,453,413.74 in 2023[21]. - The basic earnings per share for 2024 was -¥0.49, down 119.52% from ¥2.51 in 2023[21]. - The company reported a significant increase in credit impairment losses by 213.51% due to rising accounts receivable[76]. - The company reported a significant decline in operating income due to the impact of policies on its generic drug business, leading to a substantial decrease in profits[116]. Research and Development - The company is investing 30 million CNY in new technology to improve manufacturing processes and ensure compliance with Good Manufacturing Practices (GMP)[16]. - The company plans to increase its R&D budget by 15% to support the development of new drug candidates[16]. - The company has established a partnership with a leading research institution to accelerate drug discovery efforts[16]. - The company has developed a high-efficiency AI-driven drug research platform to explore new drug targets and optimize existing mature targets[39]. - The company is focusing on expanding its innovative drug pipeline and has several new projects under development[136]. Market Expansion and Strategy - The company is expanding its market presence, targeting an additional 10 provinces in China by the end of the fiscal year[16]. - The company aims to achieve a market share of 10% in the generic drug sector within the next two years[16]. - The company is actively pursuing mergers and acquisitions to enhance its product offerings and market presence, with a target of completing two acquisitions in the next year[136]. - The company plans to enter two new international markets by the end of 2024, aiming for a 10% market share in each[161]. Governance and Compliance - The report indicates that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy[4]. - The financial report is guaranteed to be true, accurate, and complete by the company's responsible personnel[4]. - The company has established a performance evaluation and incentive mechanism to ensure transparency and fairness in governance[141]. - The company maintains independent operations in assets, personnel, finance, and business, ensuring no interference from controlling shareholders[143]. - The company is committed to complying with regulatory requirements in the pharmaceutical industry to mitigate risks related to policy changes[132]. Future Outlook - The company provided a positive outlook for the next quarter, projecting a revenue growth of 20% to 600 million CNY[16]. - Future plans and development strategies mentioned in the report do not constitute commitments to investors, highlighting potential investment risks[5]. - The company aims to submit IND applications for several new drug candidates by 2025, enhancing its pipeline in the neuropathic pain and oncology sectors[97]. - The company has set ambitious performance targets for the next fiscal year, aiming for a significant increase in revenue[153]. Employee and Management Structure - The company employed 1,834 staff as of December 31, 2024, with 69.47% in technical R&D roles[74]. - The company has implemented a competitive and fair compensation system, aligning employee salaries with job responsibilities and performance contributions[179]. - The company has a stable management team with no significant changes in executive positions reported[149]. - The company has established a mentorship program to foster talent development, incentivizing mentors through awards[181]. Risk Management - The company acknowledges the risks associated with drug development failures and is implementing measures to strengthen its R&D team and optimize drug development processes[128][129]. - The company is aware of the long drug development cycles and is actively monitoring policy changes to mitigate risks related to project delays[130]. - The company has not experienced major environmental or safety incidents but recognizes the potential risks and is enhancing safety management practices[132]. Investment and Funding - The company reported a total fundraising amount of RMB 2,152,516,693.20, with a net amount of RMB 1,863,430,088.41 after deducting issuance costs of RMB 289,086,604.79[113]. - The company has allocated RMB 36,387.00 million of the oversubscription funds for permanent working capital, not exceeding 30% of the total oversubscription amount[116]. - The company has increased its investment in innovative drug research and development to counteract the decline in revenue[116]. Product Development - New product development includes the launch of a generic drug expected to generate 100 million CNY in revenue within the first year[16]. - The company is actively pursuing new drug developments, with 12 drugs in the submission stage for Class 3 and Class 4 combined[46]. - The company has submitted applications for 10 drugs in Class 3, including treatments for obstructive airway diseases and type 2 diabetes[45].

Financial Performance - The company's revenue for Q1 2025 was ¥128,727,480.49, a decrease of 40.32% compared to ¥215,702,841.54 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥26,197,617.81, representing a decline of 152.59% from a profit of ¥49,818,209.14 in the previous year[4]. - Total operating revenue for the current period was ¥128,727,480.49, a decrease of 40.4% compared to ¥215,702,841.54 in the previous period[18]. - Net profit for the current period was a loss of ¥26,197,617.81, compared to a profit of ¥49,818,209.14 in the previous period, representing a significant decline[19]. - Basic and diluted earnings per share for the current period were both -¥0.24, compared to ¥0.46 in the previous period[20]. - Other comprehensive income after tax for the current period was -¥32,349.31, compared to -¥1,349.85 in the previous period[19]. Cash Flow - The net cash flow from operating activities improved by 42.59%, amounting to -¥70,028,927.58 compared to -¥121,975,608.72 in the prior year[4]. - The company reported a total of ¥108,725,148.09 in cash inflows from operating activities, a decrease from ¥110,905,629.87 in the previous period[21]. - Investment activities generated cash inflows of ¥128,032,273.42, compared to ¥97,926,542.60 in the previous period, indicating a positive trend in investment recovery[21]. - Net cash flow from investment activities was -$88.79 million, a decrease from -$233.07 million in the previous period[22]. - Cash inflow from financing activities totaled $200 million, down from $514 million in the prior period[22]. - Cash outflow for debt repayment was $80 million, compared to $249.50 million previously[22]. - The net increase in cash and cash equivalents was -$43.19 million, improving from -$93.80 million in the previous period[22]. - The ending balance of cash and cash equivalents was $372.97 million, down from $684.65 million at the end of the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥3,773,885,876.81, reflecting a 1.42% increase from ¥3,721,188,515.50 at the end of the previous year[4]. - Current assets totaled CNY 1,610,431,297.78, up from CNY 1,545,474,358.29 at the start of the period, reflecting a growth of approximately 4.9%[14]. - Total liabilities rose to CNY 1,220,726,059.65 from CNY 1,141,798,731.22, reflecting an increase of about 6.9%[15]. - The company's equity remained stable with total equity at CNY 2,553,159,817.16, consistent with previous periods[15]. - The company reported a significant increase in contract assets, which rose to CNY 390,159,165.61 from CNY 379,655,510.32, indicating a growth of approximately 2.6%[14]. Expenses - The company experienced a 368.22% increase in financial expenses, totaling ¥3,443,240.34, primarily due to increased loan amounts and interest expenses[8]. - Total operating costs increased slightly to ¥164,765,613.68 from ¥164,553,615.62, with operating costs rising to ¥75,155,234.89 from ¥68,611,172.02[18]. - Research and development expenses decreased to ¥54,466,161.55 from ¥65,271,951.41, indicating a reduction in investment in innovation[18]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,188, with no preferred shareholders[10]. Government Support - The company received government subsidies amounting to ¥8,473,176.69, contributing to other income growth of 634.24%[8]. Return on Equity - The company's weighted average return on equity decreased to -1.02% from 1.84% in the previous year[4].

Core Viewpoint - Baicheng Pharmaceutical (301096.SZ) has revised its 2024 annual performance forecast, projecting a net loss of 31.5 million to 53.5 million yuan, a significant shift from the previously expected profit of 45 million to 65 million yuan [1][2]. Summary by Relevant Sections - **Performance Forecast Revision** - The company expects to report a net loss for 2024, marking a potential first annual loss since its listing in 2021 [1][2]. - The revised forecast indicates a substantial decline from the previous year's profit of 272 million yuan [2]. - **Factors Influencing the Revision** - The annual audit was not fully underway when the initial forecast was made, leading to a cautious approach in revenue recognition, resulting in a revenue reduction of 40 million yuan due to indications of contract termination in R&D projects [2]. - The company decided not to recognize deferred tax assets related to deductible temporary differences, leading to an increase in income tax expenses by 45 million yuan [2]. - A comprehensive assessment of accounts receivable resulted in specific provisions for bad debts, decreasing pre-tax profit by 10 million yuan [2].

Financial Forecasts - The company revised its 2024 net profit forecast to a range of 53.5 million to 63.5 million CNY, down from the previous estimate of 45 million to 65 million CNY [3]. - The adjusted net profit after deducting non-recurring gains and losses is now expected to be between 25.88 million and 35.88 million CNY, compared to the prior estimate of 26.1 million to 39.1 million CNY [4]. Revenue and Expenses - The company will reduce revenue by 40 million CNY due to indications of contract termination in R&D projects [6]. - An increase in income tax expenses by 45 million CNY is attributed to the cautious recognition of deferred tax assets related to deductible temporary differences [6]. - The company has recognized a decrease in pre-tax profit by 10 million CNY due to specific provisions for bad debts on accounts receivable [6]. Communication and Reporting - The board emphasizes the importance of improving communication with the accounting firm to enhance the accuracy of future performance forecasts [7]. - The financial data for the performance forecast revision is based on calculations from the finance department, with detailed figures to be disclosed in the 2024 annual report [8].

金十数据4月15日讯，百诚医药在互动平台表示，公司开展了多个新药研发项目，截至目前，公司已获 得1个1类创新药，10个2类创新药的临床试验批准。 百诚医药：公司已获得1个1类创新药 10个2类创新药的临床试验批准 ...

关于创新药BIOS-0618片获得临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 杭州百诚医药科技股份有限公司（以下简称"公司"）近日收到国家药品监督管 理局（NMPA）临床试验批准通知书，公司自主研发的创新药 BIOS-0618 片将开展临床 试验研究。本品此前已获得适用于神经病理性疼痛治疗的临床试验批准，本次为新增 适应症获批。现将情况公告如下： 证券代码：301096 证券简称：百诚医药 公告编号：2025-015 杭州百诚医药科技股份有限公司 阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡，其主要特征为发作性日间 过度思睡（EDS）、猝倒、入睡前幻觉、睡眠瘫痪、夜间睡眠紊乱。随着人口老龄化增 一、药品基本情况 药品名称：BIOS-0618 片 注册分类：1 类 适应症：阻塞性睡眠呼吸暂停综合征（OSA）患者日间过度思睡 申请人：杭州百诚医药科技股份有限公司 受理号：CXHL2500103、CXHL2500104 目前所处的审批阶段：IND 获批 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2025 年 1 ...

国金证券股份有限公司 关于杭州百诚医药科技股份有限公司 2024 年度持续督导培训情况报告 国金证券股份有限公司（以下简称"国金证券"或"本保荐机构"）作为杭州百 诚医药科技股份有限公司（以下简称"百诚医药"或"公司"）持续督导的保荐机构， 根据《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易 所创业板股票上市规则》等有关规定，于 2025 年 3 月 14 日对百诚医药进行了 2024 年度持续督导培训，报告如下： 一、本次培训的基本情况 1、保荐人：国金证券股份有限公司 本次持续督导培训的工作过程中，百诚医药给予了积极配合。全体参与培训的人 员均进行了认真学习，对上市公司规范运作等相关法律法规有了更系统、全面的认识。 参训人员均表示在日常经营过程中要严格遵守上市公司相关法规，依法规范运作。本 次培训达到了预期的目标，取得了良好的结果。 （此页无正文，为《国金证券股份有限公司关于杭州百诚医药科技股份有限公司 2024 年度持续督导培训情况报告》之签字盖章页） 2、保荐代表人：余波、耿旭东 3、培训时间：2025 年 3 月 14 日 4、培训地点：百诚医药会议室 5、培训人员：耿 ...

证券代码：301096 证券简称：百诚医药 公告编号：2025-014 杭州百诚医药科技股份有限公司 关于公司控制的合伙企业认购私募基金份额的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、本次交易概述 1.为提高资金利用率，实现优质资产配置目标，杭州百诚医药科技股份有限 公司（以下简称"公司"）借助专业机构的专业力量，由公司控制的杭州觅鹏企 业管理合伙企业（有限合伙）（以下简称"杭州觅鹏"）拟参与认购淮安见素产 业投资基金合伙企业（有限合伙）份额，杭州觅鹏于2025年3月25日签署《合伙 协议》。杭州觅鹏作为有限合伙人，拟以自有资金300万元认购对应的出资额。 2、本次投资未达到《公司章程》和《对外投资管理制度》规定的审议标准， 无需提交董事会和股东大会审议。本次投资资金来源于杭州觅鹏自有资金，不构 成关联交易，不构成重大资产重组。 本次与专业机构共同投资符合《深圳证券交易所上市公司自律监管指引第7 号—交易与关联交易（2023年修订）》第四十七条相关规定，本次认购份额的私 募基金为与主营业务相关的投资基金。 二、合作方基本情况 （一） 普通合伙人 ...